XNAS · Healthcare · Biotechnology
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | Q1 2026 | -0.38 | -0.30 | +21.05% | $8.7M | ✅ Beat | -1.06% | -6.83% | — |
| 2026-03-17 | Q4 2025 | -0.36 | -0.34 | +5.56% | $5.4M | ✅ Beat | +1.41% | -9.03% | +13.03% |
| 2025-11-12 |
| Q3 2025 |
| -0.31 |
| -0.10 |
| +67.74% |
| $0 |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-14 | Q2 2025 | -0.39 | 1.71 | +538.46% | $0 | mixed | +2.06% | -1.66% | -11.06% |
| 2025-03-20 | Q4 2024 | -0.34 | -0.14 | +58.82% | $0 | ✅ Beat | +0.19% | -1.95% | -4.28% |
| 2024-11-14 | Q3 2024 | -0.40 | -0.63 | -57.50% | $0 | ❌ Miss | -1.51% | -2.69% | -1.01% |
| 2024-08-12 | Q2 2024 | -0.36 | -0.26 | +27.78% | $0 | ✅ Beat | +0.61% | +5.66% | +12.93% |
| 2024-05-15 | Q1 2024 | -0.53 | -1.16 | -118.87% | $0 | ❌ Miss | -2.34% | -8.92% | -2.97% |
Showing last 8 quarters.